Research Article
BibTex RIS Cite
Year 2019, Volume: 9 Issue: 4, 391 - 394, 31.12.2019
https://doi.org/10.16899/jcm.578199

Abstract

References

  • 1. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjögren’s syndrome: new clinical and therapeutic concepts. Annals of the rheumatic diseases. 2005;64(3):347-54.2. Pertovaara M, Korpela M, Uusitalo H, Pukander J, Miettinen A, Helin H, et al. Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both). Annals of the rheumatic diseases. 1999;58(7):423-7.
  • 3. Bowman S. Primary Sjögren's syndrome. Lupus. 2018;27(1_suppl):32-5.
  • 4. Alamanos Y, Tsifetaki N, Voulgari P, Venetsanopoulou A, Siozos C, Drosos A. Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982–2003. Rheumatology. 2005;45(2):187-91.
  • 5. Lee K-A, Kim K-W, Kim B-M, Won J-Y, Kim H-A, Moon H-W, et al. Clinical and diagnostic significance of serum immunoglobulin A rheumatoid factor in primary Sjogren’s syndrome. Clinical oral investigations. 2018:1-9.
  • 6. Bournia V-K, Vlachoyiannopoulos PG. Subgroups of Sjögren syndrome patients according to serological profiles. Journal of autoimmunity. 2012;39(1-2):15-26.
  • 7. Harley JB, Alexander EL, Bias WB, Fox OF, Provost TT, Reichlin M, et al. Anti‐Ro (SS‐A) and anti‐La (SS‐B) in patients with Sjögren's syndrome. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 1986;29(2):196-206.
  • 8. Wang Y, Hou Z, Qiu M, Ye Q. Risk factors for primary Sjögren syndrome-associated interstitial lung disease. Journal of thoracic disease. 2018;10(4):2108.
  • 9. Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical applications. Disease markers. 2013;35(6):727-34.
  • 10. Sanmartí R, Ruiz-Esquide V, Hernández MV. Rheumatoid arthritis: a clinical overview of new diagnostic and treatment approaches. Current topics in medicinal chemistry. 2013;13(6):698-704.
  • 11. Baldini C, Pepe P, Quartuccio L, Priori R, Bartoloni E, Alunno A, et al. Primary Sjögren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology. 2013;53(5):839-44.
  • 12. Lim SA, Nam S, Kwok S-K, Park S-H, Chung S-H. Serologic markers are associated with ocular staining score in primary Sjögren syndrome. Cornea. 2015;34(11):1466-70.
  • 13. Giovelli RA, Santos MC, Serrano ÉV, Valim V. Clinical characteristics and biopsy accuracy in suspected cases of Sjögren’s syndrome referred to labial salivary gland biopsy. BMC musculoskeletal disorders. 2015;16(1):30.
  • 14. Liang Y, Yang Z, Qin B, Zhong R. Primary Sjögren's syndrome and malignancy risk: a systematic review and meta-analysis. Annals of the rheumatic diseases. 2014;73(6):1151-6.
  • 15. Fife RS, Chase WF, Dore RK, Wiesenhutter CW, Lockhart PB, Tindall E, et al. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Archives of internal medicine. 2002;162(11):1293-300.
  • 16. Fox RI, Chan E, Benton L, Fong S, Friedlaender M, Howell FV. Treatment of primary Sjögren's syndrome with hydroxychloroquine. The American journal of medicine. 1988;85(4):62-7.
  • 17. Price E, Rigby S, Clancy U, Venables P. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome. The Journal of rheumatology. 1998;25(5):896-9.
  • 18. Deheinzelin D, Capelozzi VL, Kairalla RA, Barbas Filho J, Saldiva P, De Carvalho C. Interstitial lung disease in primary Sjögren's syndrome. Clinical-pathological evaluation and response to treatment. American journal of respiratory and critical care medicine. 1996;154(3):794-9.
  • 19. Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. The Journal of rheumatology. 2013;40(5):640-6.
  • 20. Fox RI. Sjögren's syndrome. The Lancet. 2005;366(9482):321-31.
  • 21. Tzioufas A, Goules A. Limited efficacy of targeted treatments in Sjögren’s syndrome: why? Clinical and experimental rheumatology. 2018;36(3):27.
  • 22. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome. Annals of the rheumatic diseases. 2007;66(3):351-7.

PRİMER SJÖGREN SENDROMUNDA SEROLOJİK TETKİKLERİN TÜKRÜK BEZİ BİYOPSİ DERECESİ VE KLİNİK İLİŞKİSİNİN DEĞERLENDİRİLMESİ

Year 2019, Volume: 9 Issue: 4, 391 - 394, 31.12.2019
https://doi.org/10.16899/jcm.578199

Abstract

Giriş-Amaç: Sjögren
sendromu göz yaşı ve tükrük bezleri olmak üzere tüm ekzokrin bezleri etkileyen kronik,
sistemik otoimmün bir hastalıktır. Sjögren sendromu tanısında klinik ve seroimmünolojik
testlerden faydalanılır. Klinik bulgulara otoantikor tetkiklerin eşlik etmediği
durumlarda minör tükrük bezi biyopsi ile tanı konur. Bu çalışma primer Sjögren
sendromu tanısında kullanılan otoantikor testlerin minör tükrük bezi biyopsi
derecesi ve klinik ilişkisinin değerlendirilmesi için yapılmıştır.

Gereç-Yöntem: Bu
çalışma retrospektif olarak Ocak 2016-Aralık 2018 arasında Romatoloji Bilim
Dalında yapıldı. Çalışmaya 18 yaş üzeri 2002 Amerika-Avrupa Konsensüs
Kriterlerine göre primer Sjögren sendromu tanısı alan 40 hasta dahil edildi. Sekonder
Sjögren sendromu olan hastalar çalışmaya alınmadı.

Bulgular: Sjögren
sendromu tanısında kullanılan otoantikor testlerden ANA pozitifliği %77.75, RF
pozitifliği %27.5, SS-A pozitifliğİ %25, SS-B pozitifliği %10, RO-52
pozitifliği %27.5 olarak bulundu. Patolojik evre ile  RF, RO-52, SS-A, SS-B pozitifliği ve ANA
titresi arasında ilişki bulunmadı (p>0.05). Otoantikor testleri negatif
saptanan 9 hastaya tükürük bezi biyopsisi ile Sjögren sendromu tanısı konuldu. Göz
kuruluğu ile ANA titresi arasında ilişki bulunmadı (p>0.05).









Tartışma-Sonuç: Bu
çalışma primer Sjögren sendromu tanısında klinik bulgular varlığında minör
tükrük bezi biyopsi ile tanının doğrulanması gerektiğini göstermiştir. 






References

  • 1. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjögren’s syndrome: new clinical and therapeutic concepts. Annals of the rheumatic diseases. 2005;64(3):347-54.2. Pertovaara M, Korpela M, Uusitalo H, Pukander J, Miettinen A, Helin H, et al. Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both). Annals of the rheumatic diseases. 1999;58(7):423-7.
  • 3. Bowman S. Primary Sjögren's syndrome. Lupus. 2018;27(1_suppl):32-5.
  • 4. Alamanos Y, Tsifetaki N, Voulgari P, Venetsanopoulou A, Siozos C, Drosos A. Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982–2003. Rheumatology. 2005;45(2):187-91.
  • 5. Lee K-A, Kim K-W, Kim B-M, Won J-Y, Kim H-A, Moon H-W, et al. Clinical and diagnostic significance of serum immunoglobulin A rheumatoid factor in primary Sjogren’s syndrome. Clinical oral investigations. 2018:1-9.
  • 6. Bournia V-K, Vlachoyiannopoulos PG. Subgroups of Sjögren syndrome patients according to serological profiles. Journal of autoimmunity. 2012;39(1-2):15-26.
  • 7. Harley JB, Alexander EL, Bias WB, Fox OF, Provost TT, Reichlin M, et al. Anti‐Ro (SS‐A) and anti‐La (SS‐B) in patients with Sjögren's syndrome. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 1986;29(2):196-206.
  • 8. Wang Y, Hou Z, Qiu M, Ye Q. Risk factors for primary Sjögren syndrome-associated interstitial lung disease. Journal of thoracic disease. 2018;10(4):2108.
  • 9. Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical applications. Disease markers. 2013;35(6):727-34.
  • 10. Sanmartí R, Ruiz-Esquide V, Hernández MV. Rheumatoid arthritis: a clinical overview of new diagnostic and treatment approaches. Current topics in medicinal chemistry. 2013;13(6):698-704.
  • 11. Baldini C, Pepe P, Quartuccio L, Priori R, Bartoloni E, Alunno A, et al. Primary Sjögren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology. 2013;53(5):839-44.
  • 12. Lim SA, Nam S, Kwok S-K, Park S-H, Chung S-H. Serologic markers are associated with ocular staining score in primary Sjögren syndrome. Cornea. 2015;34(11):1466-70.
  • 13. Giovelli RA, Santos MC, Serrano ÉV, Valim V. Clinical characteristics and biopsy accuracy in suspected cases of Sjögren’s syndrome referred to labial salivary gland biopsy. BMC musculoskeletal disorders. 2015;16(1):30.
  • 14. Liang Y, Yang Z, Qin B, Zhong R. Primary Sjögren's syndrome and malignancy risk: a systematic review and meta-analysis. Annals of the rheumatic diseases. 2014;73(6):1151-6.
  • 15. Fife RS, Chase WF, Dore RK, Wiesenhutter CW, Lockhart PB, Tindall E, et al. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Archives of internal medicine. 2002;162(11):1293-300.
  • 16. Fox RI, Chan E, Benton L, Fong S, Friedlaender M, Howell FV. Treatment of primary Sjögren's syndrome with hydroxychloroquine. The American journal of medicine. 1988;85(4):62-7.
  • 17. Price E, Rigby S, Clancy U, Venables P. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome. The Journal of rheumatology. 1998;25(5):896-9.
  • 18. Deheinzelin D, Capelozzi VL, Kairalla RA, Barbas Filho J, Saldiva P, De Carvalho C. Interstitial lung disease in primary Sjögren's syndrome. Clinical-pathological evaluation and response to treatment. American journal of respiratory and critical care medicine. 1996;154(3):794-9.
  • 19. Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. The Journal of rheumatology. 2013;40(5):640-6.
  • 20. Fox RI. Sjögren's syndrome. The Lancet. 2005;366(9482):321-31.
  • 21. Tzioufas A, Goules A. Limited efficacy of targeted treatments in Sjögren’s syndrome: why? Clinical and experimental rheumatology. 2018;36(3):27.
  • 22. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome. Annals of the rheumatic diseases. 2007;66(3):351-7.
There are 21 citations in total.

Details

Primary Language Turkish
Journal Section Original Research
Authors

Muhammet Limon 0000-0002-5693-7885

Dilek Tezcan This is me 0000-0002-8295-9770

Semral Gülcemal 0000-0002-6085-9939

Sema Yılmaz 0000-0001-5076-1500

Neriman Akdam This is me 0000-0002-0204-6657

Publication Date December 31, 2019
Acceptance Date November 26, 2019
Published in Issue Year 2019 Volume: 9 Issue: 4

Cite

AMA Limon M, Tezcan D, Gülcemal S, Yılmaz S, Akdam N. PRİMER SJÖGREN SENDROMUNDA SEROLOJİK TETKİKLERİN TÜKRÜK BEZİ BİYOPSİ DERECESİ VE KLİNİK İLİŞKİSİNİN DEĞERLENDİRİLMESİ. J Contemp Med. December 2019;9(4):391-394. doi:10.16899/jcm.578199